600276 恒瑞医药
交易中 11-05 14:42:38
资讯
新帖
简况
UBS Group AG增持恒瑞医药(01276)111.7万股 每股作价约49.86港元
智通财经 · 11-03 19:30
UBS Group AG增持恒瑞医药(01276)111.7万股 每股作价约49.86港元
花旗集团在恒瑞医药的H股好仓比例下降0.18%至5.92%
南方财经网 · 11-03 17:23
花旗集团在恒瑞医药的H股好仓比例下降0.18%至5.92%
贝莱德在恒瑞医药的H股好仓比例上升0.62%至6.51%
南方财经网 · 11-03 17:20
贝莱德在恒瑞医药的H股好仓比例上升0.62%至6.51%
中邮证券：维持恒瑞医药“买入”评级，肿瘤创新药回暖，BD收入稳定
同花顺 · 11-03 15:38
中邮证券：维持恒瑞医药“买入”评级，肿瘤创新药回暖，BD收入稳定
花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团及恒瑞医药
同花顺 · 11-03 09:38
花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团及恒瑞医药
恒瑞医药(01276)截至10月末累计回购A股股份163.62万股
智通财经 · 11-02 17:21
恒瑞医药(01276)截至10月末累计回购A股股份163.62万股
摩根大通在恒瑞医药的H股好仓比例上升0.34%至10.21%
南方财经网 · 10-29
摩根大通在恒瑞医药的H股好仓比例上升0.34%至10.21%
恒瑞医药：注射用瑞康曲妥珠单抗上市申请获受理并纳入优先审评
每日经济新闻 · 10-29
恒瑞医药：注射用瑞康曲妥珠单抗上市申请获受理并纳入优先审评
【券商聚焦】群益证券维持恒瑞医药（01276）买进评级 指BD收益增厚净利
金吾财讯 · 10-29
【券商聚焦】群益证券维持恒瑞医药（01276）买进评级 指BD收益增厚净利
恒瑞医药第三季度盈利创次新高：创新药筑基，海外许可发力
财中社 · 10-29
恒瑞医药第三季度盈利创次新高：创新药筑基，海外许可发力
恒瑞医药三季度：净利润大涨89%，销售这本账在补课
红星资本局 · 10-28
恒瑞医药三季度：净利润大涨89%，销售这本账在补课
恒瑞医药HRS-8046片临床试验获批
北京商报 · 10-28
恒瑞医药HRS-8046片临床试验获批
创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道
金吾财讯 · 10-28
创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道
港股异动丨恒瑞医药H股大涨超12%，Q3业绩环比大增
格隆汇 · 10-28
港股异动丨恒瑞医药H股大涨超12%，Q3业绩环比大增
智通港股早知道 | 恒瑞医药(01276)前三季度归母净利同比增长20.38% 李宁(02331)管理层计划讨论派发特别股息
智通财经 · 10-28
智通港股早知道 | 恒瑞医药(01276)前三季度归母净利同比增长20.38% 李宁(02331)管理层计划讨论派发特别股息
净利同比增89%，“药王”恒瑞医药第三季度业绩重回正增速，赚超24亿元，期末股东增至60万户
东方财富网 · 10-27
净利同比增89%，“药王”恒瑞医药第三季度业绩重回正增速，赚超24亿元，期末股东增至60万户
恒瑞医药(01276)三季度，增长动力从哪里来？
智通财经 · 10-27
恒瑞医药(01276)三季度，增长动力从哪里来？
恒瑞医药(01276)：1类创新药注射用甲苯磺酸瑞马唑仑获批准新增适应症
智通财经 · 10-27
恒瑞医药(01276)：1类创新药注射用甲苯磺酸瑞马唑仑获批准新增适应症
第三季度营收净利环比双增，恒瑞医药业绩呈现显著回升态势
同花顺 · 10-27
第三季度营收净利环比双增，恒瑞医药业绩呈现显著回升态势
恒瑞医药Q3净利润24.58亿元，同比增长88.92%
老虎资讯综合 · 10-27
恒瑞医药Q3净利润24.58亿元，同比增长88.92%
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":50.04,"timestamp":1793860958000,"preClose":49.05,"halted":0,"volume":61898613,"delay":0,"changeRate":0.0202,"floatShares":6379000000,"shares":6637000000,"eps":1.3385,"marketStatus":"交易中","change":0.99,"latestTime":"11-05 14:42:38","open":49.12,"high":50.08,"low":49.03,"amount":3076000000,"amplitude":0.0214,"askPrice":50.04,"askSize":205,"bidPrice":50.03,"bidSize":168,"shortable":0,"etf":0,"ttmEps":1.3385,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793862000000},"marketStatusCode":2,"adr":0,"adjPreClose":49.05,"symbolType":"stock","openAndCloseTimeList":[[1793842200000,1793849400000],[1793854800000,1793862000000]],"highLimit":53.96,"lowLimit":44.14,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.87,"roa":"--","peRate":37.385133,"roe":"12.17%","epsLYR":1.19,"committee":-0.557335,"marketValue":332125000000,"turnoverRate":0.0097,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":52.65,"timestamp":1793860949147,"preClose":51.65,"halted":0,"volume":3632695,"delay":0,"premium":"-10.59"},"floatMarketCap":319205000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2680772880","title":"UBS Group AG增持恒瑞医药(01276)111.7万股 每股作价约49.86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680772880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680772880?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:30","pubTimestamp":1793705447,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月28日，UBS Group AG增持恒瑞医药(01276)111.7万股，每股作价49.8626港元，总金额约5569.65万港元。增持后最新持股数目约为1345.74万股，最新持股比例为5.21%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU1863844665.USD","BK0188","LU2580892789.USD","BK0012","BK4588","LU0405327494.USD","LU1328615791.USD","BK0239","LU2097828631.EUR","LU1820825898.SGD","LU1829250122.USD","LU2148510915.USD","LU1863844749.USD","LU1146622755.USD","LU1997245094.SGD","600276","LU2289578879.USD","LU2488822045.USD","01276","LU1997245177.USD","IE0034235071.USD","EWH","BK0183","LU1064130708.USD","LU2495084118.USD","LU2097828714.EUR","LU1997244956.HKD","BK0060","LU1655091616.SGD","BK4118","LU2097828474.EUR","BK1191","LU1064131003.USD","LU2097828557.USD","LU2543165471.USD","BK4534","LU1969619763.USD","LU0359202008.SGD","UBS","LU2580892862.HKD","LU0359201885.HKD","LU2097828805.USD","LU2328871848.SGD","LU0405327148.USD","LU0359201612.USD","BK0196","LU1580142542.USD","BK4585","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680744352","title":"花旗集团在恒瑞医药的H股好仓比例下降0.18%至5.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680744352","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680744352?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:23","pubTimestamp":1793697780,"startTime":"0","endTime":"0","summary":"南财智讯11月3日电，香港交易所披露信息显示，CitigroupInc.（花旗集团）在恒瑞医药的H股好仓（L）比例于10月28日从6.10%下降至5.92%。同时淡仓（S）比例从2.44%升至2.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033920344516.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033920344516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1506573853.SGD","LU0130517989.USD","LU1997245177.USD","LU0359201885.HKD","BK0060","IYF","LU0072461881.USD","LU0648001328.SGD","LU0477156953.USD","LU0405327494.USD","LU1997244956.HKD","LU0314106906.USD","LU2580892862.HKD","600276","LU0128525689.USD","LU2328871848.SGD","LU1969619763.USD","BK0183","LU0203347892.USD","LU2097828714.EUR","BK4585","LU2360032135.SGD","LU1244550221.USD","LU0106831901.USD","LU1244550494.USD","BK4207","LU0162691827.USD","BK4559","TFNS","LU2580892789.USD","01276","LU1144417596.USD","LU2125154935.USD","LU0130102774.USD","LU0980610538.SGD","LU2462157665.USD","LU1255011170.USD","BK0239","FTXO","LU1781817850.SGD","LU1820825898.SGD","LU0310800965.SGD","BK4504","LU1668664300.SGD","LU1146622755.USD","LU0320765646.SGD","LU0359201612.USD","LU1244550577.SGD","BK4588","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680075749","title":"贝莱德在恒瑞医药的H股好仓比例上升0.62%至6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680075749","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680075749?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:20","pubTimestamp":1793697600,"startTime":"0","endTime":"0","summary":"南财智讯11月3日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在恒瑞医药的H股好仓（L）比例于10月29日从5.89%上升至6.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033920336955.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033920336955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","LU1781817850.SGD","LU1580142542.USD","LU1064131003.USD","LU1820825898.SGD","BK0060","LU2580892862.HKD","LU1997245177.USD","LU1969619763.USD","BK0196","BK0183","LU1146622755.USD","LU2097828714.EUR","LU1997244956.HKD","LU2328871848.SGD","BK0012","600276","BK1191","LU0359201612.USD","LU1328615791.USD","LU0359202008.SGD","LU2097828631.EUR","LU2495084118.USD","LU1064130708.USD","LU2097828805.USD","BK0239","BK0188","LU2097828474.EUR","LU2580892789.USD","LU2097828557.USD","LU0359201885.HKD","LU2543165471.USD","LU1655091616.SGD","01276","LU0405327494.USD","LU1255011170.USD","LU2148510915.USD","LU2488822045.USD","LU2289578879.USD","BK0028","LU0405327148.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680748696","title":"中邮证券：维持恒瑞医药“买入”评级，肿瘤创新药回暖，BD收入稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2680748696","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680748696?lang=zh_cn&edition=full","pubTime":"2026-11-03 15:38","pubTimestamp":1793691480,"startTime":"0","endTime":"0","summary":"11月3日，中邮证券研报指出，恒瑞医药(600276.SH)肿瘤创新药回暖，BD收入稳定。26Q1-Q3归母净利润为69.2亿元(+20.4%)，26Q3归母净利润为24.6亿元(+88.9%)。前三季度仿制药收入76.1亿元(-16. ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261103/c681401132.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261103/c681401132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["161027","600276","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680790285","title":"花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团及恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2680790285","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680790285?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:38","pubTimestamp":1793669880,"startTime":"0","endTime":"0","summary":"花旗发布研报称，ESMO2026标志着中国制药及生物科技又迈出重要一步，中国原研资产于多项全球关键研究交出具说服力数据，并展现强劲的中国至全球一致性、高关注度临床结果，以及超越既有靶点 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261103/c681387507.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261103/c681387507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938","BK0012","LU2097828557.USD","LU1969619763.USD","LU1255011170.USD","LU2148510915.USD","LU0405327494.USD","BK0183","LU1997245177.USD","BK0060","BK0188","LU2495084118.USD","LU2580892789.USD","LU2488822045.USD","LU1064130708.USD","LU2580892862.HKD","BK0239","LU2097828631.EUR","LU1146622755.USD","LU1655091616.SGD","LU1997245094.SGD","LU1781817850.SGD","LU2289578879.USD","LU1997244956.HKD","LU1064131003.USD","LU2328871848.SGD","LU1328615791.USD","600276","159837","LU1580142542.USD","LU2097828714.EUR","BK0196","LU0405327148.USD","LU2097828805.USD","LU2097828474.EUR","BK0028","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680737475","title":"恒瑞医药(01276)截至10月末累计回购A股股份163.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680737475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680737475?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:21","pubTimestamp":1793611281,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至2026年10月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购A股股份163.62万股，已回购股份占公司总股本的比例为0.025%，购买的最高价为人民币46.33元/股，最低价为人民币43.10元 /股，已支付的总金额为人民币7,388.49万元(不含交易费用)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","LU2580892789.USD","02823","BK0012","03188","LU0405327494.USD","82843","02822","LU1328615791.USD","LU1820825898.SGD","02846","LU1146622755.USD","399300","600276","BK0028","LU2289578879.USD","01276","LU1997245177.USD","82846","83188","83130","LU2495084118.USD","BK0183","LU1064130708.USD","LU2097828714.EUR","LU1997244956.HKD","BK0060","LU1781817850.SGD","LU1655091616.SGD","LU2097828474.EUR","LU2543165471.USD","82822","82823","LU1969619763.USD","LU0359202008.SGD","LU2580892862.HKD","BK1147","03130","LU0359201885.HKD","LU2097828805.USD","LU2328871848.SGD","LU0405327148.USD","159982","02843","02827","BK0196","07233","LU0359201612.USD","LU1580142542.USD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679476074","title":"摩根大通在恒瑞医药的H股好仓比例上升0.34%至10.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679476074","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679476074?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:23","pubTimestamp":1793265837,"startTime":"0","endTime":"0","summary":"南财智讯10月29日电，香港交易所披露信息显示，JPMorganChase&Co.（摩根大通）在恒瑞医药的H股好仓（L）比例于10月26日从9.87%上升至10.21%。同时淡仓（S）比例从3.39%升至3.40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914315512.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914315512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2495084118.USD","600276","LU2097828631.EUR","BK0060","PGF","LU1023057109.AUD","BK0239","LU0359202008.SGD","BK4582","LU1328615791.USD","LU2543165471.USD","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","BK0188","LU0359201612.USD","LU0405327148.USD","LU0405327494.USD","LU1064130708.USD","LU2148510915.USD","BK0196","LU1146622755.USD","LU1820825898.SGD","LU2328871848.SGD","LU1255011170.USD","LU1781817850.SGD","BK0012","LU1655091616.SGD","LU1580142542.USD","BK0183","LU1997245177.USD","LU1997245094.SGD","LU2488822045.USD","BK0028","LU2097828557.USD","LU2097828714.EUR","01276","LU1064131003.USD","LU2097828805.USD","LU0359201885.HKD","LU1997244956.HKD","LU2097828474.EUR","BK1191","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679475307","title":"恒瑞医药：注射用瑞康曲妥珠单抗上市申请获受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2679475307","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679475307?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:57","pubTimestamp":1793264238,"startTime":"0","endTime":"0","summary":"【恒瑞医药：注射用瑞康曲妥珠单抗上市申请获受理并纳入优先审评】10月29日，恒瑞医药(600276.SH)公告称，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局《受理通知书》，注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914246353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914246353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU0359201885.HKD","LU1997245177.USD","LU2580892789.USD","LU1064130708.USD","LU1820825898.SGD","LU2097828714.EUR","LU2328871848.SGD","BK0239","LU1255011170.USD","LU2495084118.USD","LU0359202008.SGD","LU0405327148.USD","BK0012","LU1969619763.USD","BK0183","LU2488822045.USD","01276","BK1191","IPOS","LU1655091616.SGD","LU1997245094.SGD","LU1146622755.USD","LU1580142542.USD","LU0359201612.USD","LU2097828557.USD","LU2580892862.HKD","BK0196","LU1023057109.AUD","LU2543165471.USD","LU2097828631.EUR","LU1064131003.USD","BK0028","600276","BK0060","LU1781817850.SGD","LU1997244956.HKD","LU2097828805.USD","LU2289578879.USD","LU0405327494.USD","BK0188","LU1328615791.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679742616","title":"【券商聚焦】群益证券维持恒瑞医药（01276）买进评级 指BD收益增厚净利","url":"https://stock-news.laohu8.com/highlight/detail?id=2679742616","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679742616?lang=zh_cn&edition=full","pubTime":"2026-10-29 14:13","pubTimestamp":1793254408,"startTime":"0","endTime":"0","summary":"单季度看，Q3实现营收人民币89.5亿元，同比增长20.6%；归母净利润人民币24.6亿元，同比增长88.9%；扣非后净利润人民币25.1亿元，同比增长90.9%，主要因确认BD收益增厚利润。研报指出，BD收益大幅增厚净利，后续仍将稳步释放。2026年前三季度BD交易收入人民币27.8亿元，同比增长31.1%，主要为GSK及BMS按履约义务完成进度确认的收入以及个别已授权产品的里程碑款等。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994744","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","KCE","600276","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679474864","title":"恒瑞医药第三季度盈利创次新高：创新药筑基，海外许可发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2679474864","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679474864?lang=zh_cn&edition=full","pubTime":"2026-10-29 11:10","pubTimestamp":1793243400,"startTime":"0","endTime":"0","summary":"10月27日晚间，恒瑞医药（600276）披露2026年第三季度报告。前三季度，公司实现营业收入244.09亿元，同比增长5.26%；归母净利润69.23亿元，同比增长20.38%。进入第三季度，公司利润增速上扬，同比增长近九成。当季归母净利润24.58亿元，同比增长88.92%，规模仅次于2025年第二季度的25.76亿元，为历史单季次高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293913631165.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293913631165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","BK0060","BK0188","LU2097828557.USD","LU1655091616.SGD","BK1574","BK0028","LU1997245177.USD","06978","LU1781817850.SGD","LNGR","BK0012","LU0405327148.USD","LU0405327494.USD","LU1064131003.USD","LU2495084118.USD","LU2580892862.HKD","IBBQ","LU0359202008.SGD","LU2289578879.USD","LU2328871848.SGD","LU2097828714.EUR","LU1064130708.USD","LU1969619763.USD","BK0183","LU1255011170.USD","LU1820825898.SGD","MEDX","159992","LU2543165471.USD","BK0196","LU1146622755.USD","BK0239","LU1328615791.USD","LU0359201612.USD","600276","LU1997245094.SGD","LU1997244956.HKD","LU2097828805.USD","LU1023057109.AUD","LU2097828631.EUR","LU1580142542.USD","LU2488822045.USD","BK1161","LU2148510915.USD","LU2580892789.USD","BK1191","LU2097828474.EUR","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678461005","title":"恒瑞医药三季度：净利润大涨89%，销售这本账在补课","url":"https://stock-news.laohu8.com/highlight/detail?id=2678461005","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678461005?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:21","pubTimestamp":1793186485,"startTime":"0","endTime":"0","summary":"10月27日晚间，恒瑞医药（600276.SH）披露2026年三季报。第三季度净利润同比大涨88.92%，放在多数公司身上，这样的数字足以配得上一场庆功。但财报的字里行间，却是另一种语气。公司坦承，全年创新药销售收入的增速，与年初设定的目标相比“仍存在一定差距”。年初的目标是增长超过30%。两种说法其实都成立。恒瑞眼下手里有两本账：一本记着对外授权，一本记着国内销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283912312220.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283912312220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678651094","title":"恒瑞医药HRS-8046片临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2678651094","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678651094?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:32","pubTimestamp":1793183531,"startTime":"0","endTime":"0","summary":"10月28日，恒瑞医药发布公告称，公司子公司成都盛迪医药有限公司、上海恒瑞医药有限公司于近日收到国家药品监督管理局核准签发关于HRS-8046片的《药物临床试验批准通知书》，将于近期开展临床试验。公告显示，HRS-8046片是恒瑞医药自主研发的创新型抗肿瘤药物，拟用于治疗携带KRASG12D突变的实体瘤。目前国内外尚无同类药物上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283912223433.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283912223433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBJ","LU1146622755.USD","BK0188","PSYK","BMED","600276","LU1997245094.SGD","LU1655091616.SGD","LU2580892789.USD","LU2289578879.USD","LU1969619763.USD","BK0239","LU1997244956.HKD","LU1328615791.USD","LU1997245177.USD","BK1191","LU2097828631.EUR","BK0196","LU0359201885.HKD","MDTX","LU1580142542.USD","LU1781817850.SGD","LU1023057109.AUD","BK0060","LU2328871848.SGD","LU2097828714.EUR","LU0359201612.USD","LU0359202008.SGD","LU1064130708.USD","LU2148510915.USD","LU0405327494.USD","IBBQ","LU1064131003.USD","LU2488822045.USD","LU1255011170.USD","LU2097828805.USD","LU1820825898.SGD","LU2495084118.USD","BK0183","LU0405327148.USD","LU2097828474.EUR","BK0012","LU2543165471.USD","LU2580892862.HKD","01276","LU2097828557.USD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强，截至发稿，恒瑞医药 涨11.14%，金斯瑞生物涨9.39%，康方生物涨4.70%，诺诚健华涨3.50%，欧康维视生物-B涨3.33%，亚盛医药涨2.65%，翰森制药涨2.32%。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","01276","LU1820825898.SGD","09926","BK0183","06855","BK1576","KCE","BK1191","LU0348767384.USD","IE00B5MMRT66.SGD","BK1589","KURE","LU0417516902.SGD","LU0348783233.USD","IBBQ","LU1781817850.SGD","09969","LU0405327148.USD","BK1583","LU0417516571.SGD","LU0634319403.HKD","600276","IE00B543WZ88.USD","159992","LU1720050803.USD","LU0417516738.SGD","LU2476274720.SGD","BK0188","BK0196","LU1064130708.USD","06978","LU2328871848.SGD","03692","LNGR","01548","BK1161","LU0359201612.USD","LU0359201885.HKD","LU2289578879.USD","LU1961090484.USD","LU2097828474.EUR","MEDX","LU1997245177.USD","HK0000320264.USD","LU0348827113.USD","LU1655091616.SGD","LU1328615791.USD","01477","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678435853","title":"港股异动丨恒瑞医药H股大涨超12%，Q3业绩环比大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2678435853","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678435853?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:00","pubTimestamp":1793152832,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2097828557.USD","LU1146622755.USD","LU0359201885.HKD","LU0405327494.USD","LU2289578879.USD","LU1064130708.USD","LU0359202008.SGD","LU1255011170.USD","LU1997244956.HKD","600276","LU2495084118.USD","LU0359201612.USD","LU2488822045.USD","LU0405327148.USD","LU1023057109.AUD","LU1997245094.SGD","LU1997245177.USD","LU2580892862.HKD","LU1328615791.USD","LU1969619763.USD","LU1820825898.SGD","LU2097828631.EUR","BK0012","LU2097828474.EUR","BK1191","LU2580892789.USD","BK0183","LU1064131003.USD","BK0060","LU1580142542.USD","LU2543165471.USD","01276","LU1655091616.SGD","LU2148510915.USD","LU2328871848.SGD","LU2097828714.EUR","BK0239","LU2097828805.USD","LU1781817850.SGD","BK0188","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678824034","title":"智通港股早知道 | 恒瑞医药(01276)前三季度归母净利同比增长20.38% 李宁(02331)管理层计划讨论派发特别股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2678824034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678824034?lang=zh_cn&edition=full","pubTime":"2026-10-28 07:21","pubTimestamp":1793143290,"startTime":"0","endTime":"0","summary":"恒瑞医药前三季度归母净利约69.23亿元，同比增长20.38%基本每股收益1.05元。康希诺生物前三季度归母净利润1629.13万元 同比增长12.82%截至2026年9月30日止九个月实现营业收入8.82亿元，同比增长27.4%;归属于上市公司股东的净利润为1629.13万元，同比增长12.82%。粤海投资前三季度归属于公司所有者的溢利43.62亿港元 同比增加7.3%持续经营业务综合收入为157.11亿港元，同比增加10.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1102505929.USD","LU1048588211.SGD","LU0370786039.SGD","LU0327786744.USD","LU0541501648.USD","LU0823426308.USD","LU0359201885.HKD","BK1589","02331","LU0359201612.USD","LU0593848301.USD","LU0823426480.USD","LU1880383366.USD","BK1610","600276","01276","LU0072462343.USD","LU2045819591.USD","LU2125910500.SGD","LU0572944931.SGD","LU0048580855.USD","LU0541502299.USD","BK1191","LU2543165471.USD","BK1502","LU1102505762.USD","LU1023057109.AUD","BK1227","LU0348805143.USD","82331","LU0359202008.SGD","BK1512","LNNGY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678117092","title":"净利同比增89%，“药王”恒瑞医药第三季度业绩重回正增速，赚超24亿元，期末股东增至60万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2678117092","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678117092?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:20","pubTimestamp":1793103631,"startTime":"0","endTime":"0","summary":"10月27日盘后，恒瑞医药（600276.SH，股价45.55元，总市值3004.51亿元）披露三季报。报告显示，公司第三季度营业收入为89.53亿元，同比增长20.55%，归母净利润为24.58亿元，同比增长88.92%，扣非净利润为25.14亿元，同比增长90.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610273910334167.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610273910334167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK0028","LU1146622755.USD","LU1064130708.USD","BK0239","LU2097828714.EUR","LU1023057109.AUD","PRTO","LU1064131003.USD","LU1997245094.SGD","LU0359201885.HKD","LU1655091616.SGD","LU1580142542.USD","600276","LU2148510915.USD","LU1820825898.SGD","LU2097828474.EUR","LU2543165471.USD","LU0405327494.USD","LU1997244956.HKD","BK0196","LU1255011170.USD","LU2097828631.EUR","BK1191","LU1997245177.USD","LU2495084118.USD","LU2097828557.USD","LU0359201612.USD","01276","LU2328871848.SGD","LU2289578879.USD","LU2580892789.USD","LU2488822045.USD","BK0183","LU0359202008.SGD","LU0405327148.USD","LU2580892862.HKD","BK0188","LU1781817850.SGD","LU1969619763.USD","BK0012","BK0060","LU2097828805.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678741291","title":"恒瑞医药(01276)三季度，增长动力从哪里来？","url":"https://stock-news.laohu8.com/highlight/detail?id=2678741291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678741291?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:46","pubTimestamp":1793101590,"startTime":"0","endTime":"0","summary":"对于恒瑞医药而言，比眼下的业绩表现更值得关注的，是下一轮增长将由谁接棒。最新披露的三季报显示，2026年前三季度，恒瑞医药实现营业收入244.09亿元，同比增长5.26%；其中产品销售收入 214.76亿元，同比增长 2.52%。第三季度单季营业收入89.53亿元、归母净利润24.58亿元，分别较第二季度环比增长22.39%和12.59%。2026，恒瑞医药共有64项抗肿瘤及相关领域研究成果入选，涉及21款创新药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU1969619763.USD","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU0405327494.USD","LU0359201612.USD","BK0012","01276","LU2543165471.USD","LU1023057109.AUD","LU2097828805.USD","LU1064130708.USD","LU2097828557.USD","LU1997244956.HKD","LU1064131003.USD","LU1328615791.USD","LU1655091616.SGD","LU2097828631.EUR","LU0359202008.SGD","LU1820825898.SGD","LU0359201885.HKD","BK0183","BK0196","LU1781817850.SGD","LU2488822045.USD","LU1997245094.SGD","LU1255011170.USD","LU2097828714.EUR","BK0028","LU2580892789.USD","LU1997245177.USD","BK0060","LU1146622755.USD","BK0239","LU2148510915.USD","LU2495084118.USD","LU1580142542.USD","BK1191","LU2289578879.USD","BK0188","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678127433","title":"恒瑞医药(01276)：1类创新药注射用甲苯磺酸瑞马唑仑获批准新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2678127433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678127433?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:46","pubTimestamp":1793094382,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司收到国家药品监督管理局的通知，批准公司1类创新药注射用甲苯磺酸瑞马唑仑新增适应症，用于重症监护期间机械通气时的镇静。甲苯磺酸瑞马唑仑通过与GABAa受体结合，抑制神经元活动，从而产生镇静麻醉作用。经查询，苯磺酸瑞马唑仑2024 年全球销售额合计约为5,922万美元。截至目前，注射用甲苯磺酸瑞马唑仑相关项目累计研发投入约22,250万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1255011170.USD","MEDX","LU1146622755.USD","BK1191","BK0196","LU1997244956.HKD","LU1781817850.SGD","LU1328615791.USD","BK1574","LU2097828805.USD","LU2495084118.USD","LU1997245094.SGD","LU2097828557.USD","LU1820825898.SGD","LU0359201612.USD","LU2580892862.HKD","LU2580892789.USD","LU2488822045.USD","LU0359201885.HKD","159992","LU1580142542.USD","LU2097828631.EUR","LU1064131003.USD","01276","600276","IBBQ","LU1023057109.AUD","LNGR","06978","LU2097828474.EUR","BK0060","LU2328871848.SGD","LU2543165471.USD","LU2289578879.USD","BK0188","LU2097828714.EUR","BK1161","BK0239","BK0028","LU0405327148.USD","LU1997245177.USD","LU0405327494.USD","BK0183","BK0012","LU1969619763.USD","LU1064130708.USD","LU0359202008.SGD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678012298","title":"第三季度营收净利环比双增，恒瑞医药业绩呈现显著回升态势","url":"https://stock-news.laohu8.com/highlight/detail?id=2678012298","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678012298?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:08","pubTimestamp":1793092080,"startTime":"0","endTime":"0","summary":"10月27日晚，恒瑞医药发布2026年第三季度报告。前三季度，公司实现营业收入244.09亿元，同比增长5.26%；其中产品销售收入214.76亿元，同比增长2.52%。归属于上市公司股东的净利润69.23亿元 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261027/c681142929.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261027/c681142929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193209053","title":"恒瑞医药Q3净利润24.58亿元，同比增长88.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193209053","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193209053?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:44","pubTimestamp":1793090688,"startTime":"0","endTime":"0","summary":"10月27日，$恒瑞医药(01276)$公告，2026年第三季度营业收入89.53亿元，同比增长20.55%；净利润24.58亿元，同比增长88.92%；扣非净利润25.14亿元，同比增长90.93%。2026年前三季度营业收入244.09亿元，同比增长5.26%；净利润69.23亿元，同比增长20.38%；扣非净利润62.43亿元，同比增长11.70%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药Q3净利润24.58亿元，同比增长88.92%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892862.HKD","LU1997245177.USD","LU1655091616.SGD","LU2097828805.USD","LU1580142542.USD","LU1997244956.HKD","LU2543165471.USD","LU2580892789.USD","LU2495084118.USD","600276","LU2097828631.EUR","01276","LU0359202008.SGD","LU2097828474.EUR","LU0359201612.USD","LU1820825898.SGD","LU0405327494.USD","BK0183","BK0012","LU2289578879.USD","LU1023057109.AUD","LU2097828714.EUR","LU1064130708.USD","BK0239","LU2097828557.USD","LU2488822045.USD","BK0188","LU1969619763.USD","BK1191","LU1255011170.USD","BK0196","LU1781817850.SGD","LU2328871848.SGD","BK0028","LU1064131003.USD","BK0060","LU1328615791.USD","LU0405327148.USD","LU2148510915.USD","LU0359201885.HKD","LU1146622755.USD","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793860959777,"stockEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0392},{"period":"3month","weight":-0.0587},{"period":"6month","weight":-0.0672},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.1732}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.0406},{"period":"3month","weight":-0.0549},{"period":"6month","weight":-0.1181},{"period":"1year","weight":-0.0692},{"period":"ytd","weight":-0.0712}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"604325人(较上一季度增加12.09%)","perCapita":"10555股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}